Barclays Reiterates Buy Rating on RXO
Barclays maintains its buy rating on RXO, setting a price target of $28, a 4.09% upside from the current price.
Key Points
- Barclays analyst Brandon Oglenski reiterated a buy rating on RXO with a $28 price target on June 26, 2026.
- Barclays's $28 price target implies 4.09% upside from RXO, Inc.'s ($RXO) current $26.90 share price.
- Shares of RXO traded at $26.9 on Saturday, reflecting ongoing interest from institutional investors.
- Insider activity includes significant trades by CEO Andrew Wilkerson, while Orbis Allan Gray and others adjusted their RXO holdings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Barclays analyst Brandon Oglenski reiterated a buy rating on RXO on June 26, 2026, setting a price target of $28. This reaffirmation underscores the firm's positive outlook for the company.
Barclays vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in RXO
Several institutional investors have recently adjusted their positions in RXO. Orbis Allan Gray Ltd increased its holdings by 1,720,219 shares, bringing its total to about 36.4 million shares valued at approximately $532.1 million, marking a 5.0% increase. MFN Partners Management, LP also added 532,276 shares, now holding about 28.1 million shares worth $410.9 million, a 1.9% rise. BlackRock, Inc. grew its stake by 267,801 shares to a total of around 24.2 million shares valued at $353.3 million, reflecting a 1.1% increase. Finepoint Capital LP boosted its position by 684,829 shares, ending with about 10.1 million shares valued at $147.3 million, a 7.3% increase. Both Vanguard Portfolio Management LLC and Vanguard Capital Management LLC opened new positions, with holdings of approximately 9.0 million and 7.4 million shares, respectively.
RXO, Inc. Stock Up 22.8%
Shares of RXO traded near $26.9 on Saturday. The stock has been showing interest from both analysts and institutional investors, with a range of price targets reflecting varying levels of optimism.
$RXO price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at RXO, Inc.
Recent insider activity at RXO includes several transactions by CEO Andrew Wilkerson and Chief Accounting Officer Daniel Morris. On May 15, 2026, Wilkerson both bought and sold 168,943 shares, while Morris acquired 13,377 shares. Earlier, on May 2, 2026, Wilkerson made several trades, including selling 40,370 shares at an average price of $19.59.
Analysts Set New Price Targets
On June 26, 2026, Barclays maintained its buy rating on RXO with a price target of $28. Earlier, on May 15, 2026, Stifel upgraded the stock to a buy with a $22 target. Other firms like UBS and Citigroup maintained hold ratings with targets of $22 and $24, respectively. The consensus among analysts suggests a range of opinions, with a general buy recommendation prevailing.
Bottom Line
Barclays' reiteration of a buy rating for RXO, along with a $28 price target, reflects confidence in the company's prospects. Institutional interest and insider transactions indicate active engagement with RXO's stock. As always, investors should consider these insights as part of a broader investment strategy, remembering that analyst ratings reflect opinions at a specific point in time.
Get RXO, Inc. alerts
New 13F filings, insider trades, and analyst moves on $RXO, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.